

Stem Cell Breakthrough: Reversing Type 1 Diabetes with Autologous Transplant

Alya Almahafdha*

Research Unit, Nab'a Al-Hayyat Foundation for Medical Sciences and Health Care, Najaf, Iraq.

*Correspondence to: Alya Almahafdha (E-mail: alya.almahafdha@gmail.com)

(Submitted: 16 October 2024 – Revised version received: 05 November 2024 – Accepted: 29 November 2024 – Published online: 26 December 2024)

Keywords: Stem cells, diabetes, autografts

Dear Editor,

I am writing to highlight a groundbreaking medical achievement that has recently captured global attention: the reversal of type 1 diabetes in a young woman through a pioneering stem cell transplant. This remarkable success not only offers hope to millions living with diabetes but also underscores the transformative potential of personalized medicine.¹

The patient, a 25-year-old woman, underwent a revolutionary 30-minute procedure, carried out in June 2023, involving the autologous transplant of islets derived from chemically induced pluripotent stem cells into the woman's abdominal muscles. This approach addresses the root cause of type 1 diabetes by restoring the body's ability to produce insulin naturally, eliminating the need for lifelong insulin injections. The results of this treatment, reported in *Cell Journal*, demonstrate sustained blood sugar regulation without external insulin support.²

This milestone exemplifies the power of stem cell technology and its application in personalized healthcare. By tailoring therapies to individual patients, such advancements are redefining how we approach chronic diseases, focusing on long-term solutions rather than symptom management. It also

provides a promising roadmap for tackling other autoimmune and degenerative conditions.³

However, this breakthrough raises important questions about accessibility and scalability. As the costs of such treatments remain high, it is crucial that healthcare systems and policymakers work towards making these life-changing therapies widely available. Additionally, continued investment in research and clinical trials will be vital to refine these methods and address potential risks.

I urge your publication to spotlight such achievements more frequently, as they serve to educate and inspire readers about the incredible possibilities of modern medicine. Stories like this remind us that with perseverance and innovation, we can overcome even the most daunting medical challenges.

Thank you for considering my submission.

Sincerely,
Alya Almahafdha

Conflict of Interest

None. ■

Reference

1. Swart, J. F., Delemarre, E. M., Van Wijk, F., Boelens, J. J., Kuball, J., Van Laar, J. M., & Wulffraat, N. M. (2017). Haematopoietic stem cell transplantation for autoimmune diseases. *Nature Reviews Rheumatology*, 13(4), 244-256.
2. Wang, S., Du, Y., Zhang, B., Meng, G., Liu, Z., Liew, S. Y., ... & Shen, Z. (2024). Transplantation of chemically induced pluripotent stem-cell-derived islets under abdominal anterior rectus sheath in a type 1 diabetes patient. *Cell*, 187(22), 6152-6164.
3. Goetz, L. H., & Schork, N. J. (2018). Personalized medicine: motivation, challenges, and progress. *Fertility and sterility*, 109(6), 952-963.

This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.